MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRD’s growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain  ...